Page last updated: 2024-10-17

3,4-dihydroxyphenylacetic acid and Huntington Disease

3,4-dihydroxyphenylacetic acid has been researched along with Huntington Disease in 15 studies

3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.

Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)

Research Excerpts

ExcerptRelevanceReference
"In the BACHD model of Huntington's disease we demonstrate that the vector can be kept in a continuous ON-state for extended periods of time."1.48Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector. ( Bähr, M; Cheng, S; Déglon, N; Konstantinova, P; Kügler, S; Liefhebber, J; Mazur, A; Pythoud, C; Raina, A; Rey, M; Streit, F; Tereshchenko, J; Vachey, G; Zimmer, V, 2018)

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19903 (20.00)18.7374
1990's2 (13.33)18.2507
2000's6 (40.00)29.6817
2010's4 (26.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheng, S1
Tereshchenko, J1
Zimmer, V1
Vachey, G1
Pythoud, C1
Rey, M1
Liefhebber, J1
Raina, A1
Streit, F1
Mazur, A1
Bähr, M1
Konstantinova, P1
Déglon, N1
Kügler, S1
Puginier, E1
Bharatiya, R1
Chagraoui, A1
Manem, J1
Cho, YH1
Garret, M1
De Deurwaerdère, P1
Renoir, T1
Argyropoulos, A1
Chevarin, C1
Lanfumey, L1
Hannan, AJ1
Chen, S1
Zhang, XJ1
Xie, WJ1
Qiu, HY1
Liu, H1
Le, WD1
Kraft, JC1
Osterhaus, GL1
Ortiz, AN1
Garris, PA1
Johnson, MA1
Zádori, D1
Geisz, A1
Vámos, E1
Vécsei, L1
Klivényi, P2
Lastres-Becker, I1
de Miguel, R1
De Petrocellis, L1
Makriyannis, A1
Di Marzo, V1
Fernández-Ruiz, J2
de Lago, E1
Ortega-Gutiérrez, S1
Cabranes, A1
Pryce, G1
Baker, D1
López-Rodríguez, M1
Ramos, JA1
Walsh, FX1
Bird, ED2
Stevens, TJ1
Melamed, E1
Hefti, F1
Nakazato, T1
Akiyama, A1
Andreassen, OA1
Ferrante, RJ1
Dedeoglu, A1
Mueller, G1
Lancelot, E1
Bogdanov, M1
Andersen, JK1
Jiang, D1
Beal, MF1
Rebec, GV1
Barton, SJ1
Ennis, MD1
Garrett, MC1
Soares-da-Silva, P1
Isacson, O1
Brundin, P1
Gage, FH1
Björklund, A1

Other Studies

15 other studies available for 3,4-dihydroxyphenylacetic acid and Huntington Disease

ArticleYear
Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector.
    Experimental neurology, 2018, Volume: 309

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Disease Models, Animal; Gene Expression

2018
Early neurochemical modifications of monoaminergic systems in the R6/1 mouse model of Huntington's disease.
    Neurochemistry international, 2019, Volume: 128

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amines; Brain; Disease Models, Animal; Dopamine; D

2019
Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.
    Pharmacology, biochemistry, and behavior, 2014, Volume: 127

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitor

2014
A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
    CNS neuroscience & therapeutics, 2015, Volume: 21, Issue:8

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Survival; Corpus Striatum; Disease Models, Animal; DNA

2015
In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid.
    Neuroscience, 2009, Jul-07, Volume: 161, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Central Nervous System Agents; Chroma

2009
Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
    Pharmacology, biochemistry, and behavior, 2009, Volume: 94, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal;

2009
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
    Journal of neurochemistry, 2003, Volume: 84, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids, Neutral; Animals; Arachidonic Acids; Basal Ganglia; Can

2003
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2006, Volume: 16, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D

2006
Monoamine transmitters and their metabolites in the basal ganglia of Huntington's disease and control postmortem brain.
    Advances in neurology, 1982, Volume: 35

    Topics: 3,4-Dihydroxyphenylacetic Acid; Basal Ganglia; Dopamine; Homovanillic Acid; Humans; Huntington Disea

1982
Huntington chorea is not associated with hyperactivity of nigrostriatal dopaminergic neurons: studies in postmortem tissues and in rats with kainic acid lesions.
    Neurology, 1982, Volume: 32, Issue:6

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Diseases; Corpus Striatum; Dopamine; Female; Homovani

1982
In vivo electrochemical measurement of the long-lasting release of dopamine and serotonin induced by intrastriatal kainic acid.
    Journal of neurochemistry, 1997, Volume: 69, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Ascorbic Acid; Circadian Rhythm; Corpus Striatum; Dopamine;

1997
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jan-01, Volume: 20, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist

2000
Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2002, Jan-15, Volume: 22, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Ascorbic Acid; Behavior, Animal; Body Weight; Corpus Striat

2002
Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington's disease: evidence for an overactive dopaminergic brain transmission.
    Journal of neurochemistry, 1992, Volume: 58, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Biogenic Amines; Brain; Dopamine; Female; Humans; Huntington

1992
Neural grafting in a rat model of Huntington's disease: progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting.
    Neuroscience, 1985, Volume: 16, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Choline O-Acetyltransferase; Corpus Striatum; Disease Model

1985